Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) Equity Average (2018 - 2025)

Historic Equity Average for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $643.7 million.

  • Bicycle Therapeutics' Equity Average fell 2448.62% to $643.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $643.7 million, marking a year-over-year decrease of 2448.62%. This contributed to the annual value of $582.0 million for FY2024, which is 8138.77% up from last year.
  • Per Bicycle Therapeutics' latest filing, its Equity Average stood at $643.7 million for Q3 2025, which was down 2448.62% from $704.6 million recorded in Q2 2025.
  • Bicycle Therapeutics' 5-year Equity Average high stood at $852.4 million for Q3 2024, and its period low was $118.8 million during Q1 2021.
  • Moreover, its 5-year median value for Equity Average was $320.8 million (2022), whereas its average is $414.4 million.
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 18478.6% in 2022, then crashed by 2780.18% in 2023.
  • Quarter analysis of 5 years shows Bicycle Therapeutics' Equity Average stood at $258.5 million in 2021, then rose by 8.35% to $280.1 million in 2022, then surged by 40.46% to $393.5 million in 2023, then soared by 106.38% to $812.0 million in 2024, then dropped by 20.73% to $643.7 million in 2025.
  • Its last three reported values are $643.7 million in Q3 2025, $704.6 million for Q2 2025, and $766.7 million during Q1 2025.